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Abstract Results
Recent studies suggest that trace element copper (Cu) plays a key role in cancer 
progression. Cu-dependent signaling pathways in cancer cells are poorly understood and 
are being actively investigated. In a recently published PNAS paper, we demonstrated that 
ATP7A copper transporter promotes breast and lung tumor growth and spread in mice by 
activating pro-cancerous enzyme, lysyl oxidase (LOX). Therefore, we propose that 
blocking ATP7A using small molecule inhibitors could be a powerful approach in blocking 
cancer progression. We screened for inhibitors of ATP7A using a structure-based virtual 
screen of ATP7A-interacting drug-like compounds, resulting in identification of our lead 
compound, MKV3. We used microscale thermophoresis and standard enzyme activity 
assays to measure the binding affinity of MKV3 to ATP7A and test the effect of MKV3 on 
ATP7A-dependent LOX and tyrosinase enzymes. In vitro scratch and tumorigenesis assays 
were performed to test the effect of MKV3 on cancer cell migration and tumor growth.
Microscale thermophoresis experiments revealed that MKV3 binds to ATP7A with 
nanomolar affinity and is a potent inhibitor of ATP7A-dependent LOX activity and cell-
migration of 4T1 breast, LLC and A549 lung cancer cells. Moreover, MKV3 inhibited 
ATP7A-dependent tyrosinase activity in B16 melanoma cells and suppressed B16 
tumorigenesis in vivo. In summary, these studies have identified a novel first-in-class 
high-affinity inhibitor of ATP7A and provide a framework to design MKV3 derivatives with 
improved therapeutic efficacy in mouse models of cancer. Our findings have the potential 
for a sustained and powerful impact in cancer therapy. 
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Fig. 2. A structural model of ATP7A highlighting putative Cu-binding triad of D, E and M 
amino acids near the platform and a pocket targeted for drug design. A) The ATP7A protein 
(backbone view) highlighting the conserved triad of closely arranged Met-Glu-Asp at the mouth 
of the funnel. B) Pipeline for identification of inhibitors of ATP7A C) A close-up of this region 
showing Cu bound within the triad in a predicted trigonal planar configuration. D) A space-
filling model highlighting the pocket and the location of our lead compound (MKV3in cyan) 
docked within the pocket.
1. The discovery of the first inhibitor of any heavy metal ion transporter.
2. The innovative use of a Cu transport inhibitor to block the activity of LOX 
enzyme, cancer cell migration and tumorigenesis
The rationale for targeting ATP7A as a novel anticancer strategy – ATP7A belongs
to the family of P1B type ATPases. It is ubiquitously expressed and is predominantly
localized in the trans-Golgi network (TGN) where it serves two important functions.
These include 1) copper export from cells which is coupled with ATP7A trafficking to
the plasma membrane 2) copper transport into the Golgi complex to LOX enzyme.
The most widely reported Cu-dependent pathway that contributes to cancer involves
the LOX enzyme. Therefore, blocking the delivery of copper to the LOX enzyme
represents an innovative and powerful strategy to block LOX-dependent
malignancies. The significance of our study is the innovative use of Cu transport
inhibitors as novel chemotherapeutic agents. This study has the potential to pave
the way for clinical studies with MKV3 or its derivatives.
Fig. 4. MKV3 inhibits copper stimulated trafficking of ATP7A.  ATP7A protein is 
shown in green (Alexa488) and nuclei were labeled with DAPI (blue).
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Fig.1. Schematic model of the role of ATP7A in LOX-mediated  tumor metastasis.  Cu enters the cell 
through high affinity Cu importer (CTR1) and is transported to ATP7A via ATOX1 protein. The ATP7A Cu 
transporter delivers Cu into the lumen of the trans-Golgi network to metallate LOX protein, which plays 
key roles in tumor metastasis by collagen crosslinking and integrin mediated activation of focal 
adhesion kinase (FAK1), a key regulator of cell migration and invasion.
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Fig. 3. MKV3 inhibits ATP7A activity in vitro and in vivo (A) Analysis of MKV3 binding to 
ATP7A using microscale thermophoresis with normalized fluorescence (Fnorm) on y-axis 
and inhibitor concentration on x-axis .B) MKV3 inhibits tyrosinase activity in B16 
melanoma cells. In-situ tyrosinase activity was measured in B16-WT cells treated with 
MKV3. Cells were treated with 5 µM MKV3or DMSO for 24 hrs and then tyrosinase activity 
was measured as the conversion of colorless L-DOPA to dopachrome. (C) Quantification of 
tyrosinase activity in B16-WT cells treated for 24 h with or without MKV3 (mean ± SEM; 
****p < 0.0001). (D and E) Intratumoral injection of MKV3 in B16 melanoma tumor 
bearing C57/BL6 mice. Tumor tyrosinase activity and weights are shown (mean ± SEM; 
***p < 0.001; ****p < 0.0001). 
Fig. 5. MKV3 inhibits LOX activity and cancer cell migration (A) Immunoblot analysis of 
ATP7A in LLC and A549 cells. (B and D) Invitro scratch assay demonstrating MKV3 reduces the 
motility of mouse LLC and human A549 lung cancer cells.  Images show the extent of gap 
closure 24 h after scratch formation in the presence or absence of MKV3. Dashed lines indicate 
scratch starting points. Cell migration rate is shown (mean ± SEM; ****p < 0.0001). (C and E) 
LOX activity in the conditioned media of wild type mouse LLC and human A549 cells treated for 
24 h with MKV3 or DMSO control (mean ± SEM; ***p < 0.001; RFU, relative fluorescence 
units). 
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